drugset / Trial / NCT01880827

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

NCT01880827

Non-randomizedParallel-groupOpen-labelBasic science

Summary

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI \> 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis. The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

Timeline

Start
2013-01
Primary completion
2015-11
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator GLP-1 Peptide
Subject Glucose-dependent Insulinotropic Polypeptide Peptide